Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
With
Cystic Fibrosis Foundation
Novo Nordisk A/S
The primary objective of this research is to determine whether treatment with either insulin or an oral diabetes agent that increases endogenous insulin secretion will improve BMI and pulmonary function in cystic fibrosis patients who have diabetes without fasting hyperglycemia.
Age
16–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Diabetic glucose pattern by oral glucose tolerance test (OGTT) of \>200 at 120 min. (stable and healthy at time of OGTT)
Fasting glucose levels \<126.
Weight stable within 5% in previous 3 months.
Free from illness for two months.
Male and female 16 and older, who are done growing
Willing to come in for visits every 3 months.
Patients receiving infrequent short bursts of systemic glucocorticoids may be considered for the study inclusion if: a. they have not received systemic glucocorticoids steroids for at least one month, b. they did not receive the steroids for more than 14 consecutive days or 28 days total in six months
Clareo Health | Diabetes Therapy to Improve BMI and Lung Function in CF
